James York | Head of Sales and Business Development
James is a graduate of East Tennessee State University where he majored in Exercise Physiology and prepared for medical school. Even though his interest was always focused on medicine and science, his first career position was a trader of equities and options on the Southwest Securities Trading Floor. Desiring to enter the healthcare sector and return to his roots, he leveraged his experience from the trading floor to start capitalizing, managing and operating various healthcare companies. James has had involvement in durable medical equipment, spinal medical devices, intra-operative neuromonitoring, clinical research, networking, pharmacies and laboratories. He has had many roles within each company including VP of Sales, President, and CEO – for companies both private and public. James is extremely excited about contributing to Molecular Testing Labs. He believes the market is craving the combination of scientific advancements and business ethics that only Molecular can deliver in the laboratory space.
Charles Sailey, MD, MS, FCAP | Laboratory Director and R&D Director
Dr. Charles Sailey obtained dual master degrees in cell biology and biotechnology before medical training. After obtaining his medical degree from Ross University School of Medicine, he completed residency training in Anatomic & Clinical Pathology at the University of Maryland, followed by fellowship training in Molecular Genetic Pathology at the University of North Carolina. As medical and scientific director of the Molecular Genetic Pathology, Molecular Microbiology, Metabolic Genetics, and Clinical Chemistry laboratories at Arkansas Children’s Hospital, he planned, designed, and coordinated the construction of a human genetics laboratory in 2011. Since that time, the laboratory has thrived and is now offering a full genetic test menu, including targeted mutation analysis using Sanger sequencing, MLPA, and copy-number variation using a SNP microarray, among others. He had several ongoing internal research projects, including the construction of a 15 target plasmid for limit-of-detection and QA studies (patent pending) used with various PCR assays. Other projects included downstream analysis of archived DNA correlated with degree of apoptotic laddering, correlation studies between home brew and commercial platforms for various molecular assays (including C. diff, sepsis, respiratory infections, PCR, and DNA sequencing), and genotyping various strains of infectious organisms in Arkansas. He also spearheaded an extensive review of all send-out genetic tests for appropriateness and cost effectiveness at a large pediatric hospital. He currently has two larger studies still underway; one involves characterizing miRNA biomarkers in children who have had LVAD placement to help stratify individuals with reverse remodeling from those advancing to end-stage heart failure. The other involves creating a custom next-generation sequencing panel looking at genes involved in psychiatric drug metabolism for non-responsive patients. Recently, he developed the next generation sequencing core facility at Arkansas Children’s Hospital, with custom designed novel autism and hereditary disease gene panels. Dr. Sailey has over 40 peer reviewed publications, book chapters, and presentations, including data presented at national conferences.
Adam Blackwell | Head of Laboratory Operations and R&D
Adam has a B.S. in Nuclear Engineering Technology and a B.A. in Business Administration and spent 10 years as a Navy Nuclear Submariner in the US Navy. Adam spent 13 years in the semiconductor industry working mostly in the field at customer sites in the US. Additionally, he spent time setting up a new sales and support facility in a small Italian village. After five years in Europe, Adam joined a solar power capital equipment company as a Director focused primarily on procurement and supply chain management. This role allowed Adam the opportunity to establish an international supply chain network that expanded from several locations in Europe to numerous locations in China, South Korea and Taiwan. Adam’s entrepreneurial spirit then prompted him to start-up six direct access laboratory testing collection centers in the Pacific Northwest and later added two wellness centers focusing on Medical Weight-Loss and Bio-Identical Hormone Replacement Therapy programs. Following, Adam joined his partners in the creation and development of Molecular Testing Labs™. Adam deeply believes that every person, no matter what their level of economic means, should have direct access to laboratory testing. “We live in an age of technology where people have the ability to learn more about their personal health than at any time in our history. Through Molecular Testing Labs™, “we want to empower people to be a part of their personal health management by direct access testing” states Adam. “Clearly, this needs to be done in partnership with the physician and should include a conversation that is based on open information about our body’s genetic and molecular make-up”.
Peter Flynn | Head of Logistics and Support Services
After earning an Associate Degree from Universal Technical Institute in Phoenix, AZ, Pete joined the US Navy where he was selected to serve as a technical supervisor and operator for the world’s newest and most complex shipboard RADAR system. Following sea duty including Operation Desert Storm, Pete traveled from coast to coast training new crews and co-authoring several technical operations documents for the US and Japanese Navies. Pete spent 15 years in the semiconductor industry starting up new factories, implementing new service contracts and developing and deploying cutting edge technical programs throughout the US, Europe and Asia. Pete’s desire to help people combined with a passionate entrepreneurial spirit led him to join his partners in the start-up and day to day operation of several medical testing collection centers throughout the Pacific Northwest. Creation and development of Molecular Testing Labs soon followed. “Medical providers and their patients depend on our services being 100% accurate and delivered in a timely manner. Continual advancements in medical testing deliver amazing benefits but nothing is more exciting and motivating then stories from providers detailing how our testing has benefited their patient. At Molecular Testing Labs we constantly improve our capabilities to provide nothing short of a world class product – lives truly can depend on it.”
Dave DeLong | Head of Business Administration
Dave serves Molecular Testing Labs as Head of Administrative Services. In this capacity, he has oversight of Legal, Compliance, Human Resources and Finance. Dave has had a diverse career and has achieved exceptional successes at every level of management. He retired from Applied Materials in 2006 as Senior Director of Operations. In retirement, Dave’s entrepreneurial spirit emerged and he has been instrumental in the creation and management of several successful companies including GTSP Global, CHP Investments and CHP-ID Investments. Dave and his wife Karen have raised three children – Bridget, Will and Ben. They make their home in Austin, Texas.“At Molecular Testing Labs, we have a very simple ideology. It is to drive the leading edge of innovative healthcare testing solutions, make these solutions available to patients who require easy, affordable access, and maintain the highest level of compliance and ethical standards. We have found that these simple ideals have had a profound impact on our company’s culture. More than 61% of our employees have been with the company for more than three years. We have also discovered that bringing innovative change to the healthcare industry is difficult and often met with skepticism. We are breaking down those barriers and intend to have a long-lasting impact on the delivery of advanced, affordable care to those who need it.”
Siobhan McKenny, BS, CTS | QA/QC Director & Toxicology Lab Manager
As Laboratory Manager of Toxicology, Siobhan brings 34 years of forensic and clinical toxicology experience to Molecular Testing Labs (Molecular). Prior to Molecular, Siobhan was Research and Development technologist at Legacy Laboratory Services (LLS) where she worked for twenty years. As the R & D Specialist, she was responsible for the research, validation and implementation of the majority of Laboratory Developed Tests at LLS. She also held several different positions including; QA/QC Officer, Alternate Responsible Person, Certifying Scientist, and Technical Specialist. She received her license as a Clinical Toxicologist Scientist in 1987 and graduated from California State University-Sacramento with a BS in Biological Science with emphasis in Clinical Laboratory Technology. Siobhan is excited to be working with Molecular Testing Labs™ and the first thing she noticed was the motivation and excitement of fellow employees and her staff. Siobhan has tremendous passion for her work and loves what she does. Outside of work she enjoys skiing, working out, and promoting a healthy lifestyle for her children
Chris Hemphill | Lab Manager – Infectious Disease
Chris joined Molecular in early 2015 after relocating to the Pacific Northwest from Arkansas Children’s Hospital. His background is in molecular biology and immunology with regard to infectious disease. Chris has more than 20 years of clinical and research experience working in CLIA and CAP accredited laboratories. He is responsible for the day-to-day operations and new assay development in the Infectious Disease laboratory.
Mariko Nakano PhD | Senior Scientist
Dr. Mariko Nakano joined the Molecular Testing Labs after completing a post-doctoral fellowship at the U.S. Food and Drug Administration, where she studied the highly polymorphic drug-metabolizing enzyme CYP2D6. Her research focus was to determine and predict CYP2D6-mediated drug-drug interactions for various genotypes. Before the FDA fellowship, she investigated the molecular mechanism of CYP3A4 inactivation by bioactivated ritonavir as a post-doctoral fellow under Dr. Kent Kunze in the University of Washington Medicinal Chemistry Department. She received her Ph.D. in Medicinal Chemistry from the University of Washington under the supervision of Dr. Allan Rettie in 2011. Her graduate work included characterizing the role of a previously orphan cytochrome P450 enzyme – CYP4V2 – in saturated and unsaturated fatty acid homeostasis. Dr. Nakano has published her work in multiple peer-reviewed journals and presented her research at national and international conferences.
Kelly T. Chauvin-Fobes, PharmD | Clinical Scientist
Kelly Chauvin-Fobes graduated with honors from Pennsylvania State University where she studied Biochemistry and Molecular Biology. She received her Doctor of Pharmacy degree from Samford University in Birmingham, AL. Her eclectic background includes experience in the pharmaceutical industry, clinical research, fitness training and pharmacy practice. When not at Molecular, Kelly enjoys snowboarding, downhill mountain biking and competing in CrossFit. She is passionate about helping people reach their individual goals while living happier and healthier lives. “Personalized medicine will be the standard of care in the near future, and I am so excited to be on the leading edge of this transformation with an industry-leading company!”
Teresa D. Dodd | Sr. Director, Revenue Cycle
Teresa has spent over 20 years in healthcare financial management. This experience started at Blue Cross Blue Shield of Missouri in sales, then Medical Management then on to Provider Relations and Contracting. From there she managed the reimbursement department for three hospitals for one of the largest health systems in Missouri, BJC Healthcare. Teresa received her Lean Sigma certification at BJC while working for corporate finance where she developed her passion for change leadership and process improvement. After BJC, Teresa managed the central business office for a nation-wide, post-acute, rehabilitation hospital organization in St. Louis then moved to Centene Corporation, one of the nation’s largest Managed Medicaid companies. At Centene Teresa was responsible for the successful implementation of claims operations for all new Centene health plans. Teresa is currently pursuing her MBA at Washington University in St. Louis, Missouri. Most of Teresa’s personal time is spent with her two daughters, supporting their extracurricular activities, relaxing at the lake, or cheering on her beloved St. Louis Cardinals. Teresa eagerly joined the Molecular team because of her passion for the technology and services offered and to offer her background and experience to ensure the Molecular Revenue Cycle operates with integrity, efficiency and compassion.
Megan Callahan | General Counsel
Megan graduated from George Fox University magna cum laude with a Bachelor of Arts degree in social and behavioral sciences, and earned her Juris Doctor degree from Willamette University College of Law. Prior to joining Molecular Testing Labs, Megan practiced business and corporate law in the Salem and Portland area. She provided legal and business advice to small and large companies focusing on entity formation, ongoing business administration, strategic planning, regulatory compliance, contract drafting and negotiations, trademark and copyright protection, and general employment guidance. In Megan’s role as General Counsel she oversees all legal affairs and provides legal advice related to the development and marketing of molecular testing, Medicare and Medicaid program compliance, healthcare fraud and abuse risk management, trademark protection, contract drafting and negotiations, and general employment matters. Megan also provides leadership for the company’s regulatory affairs, ethics and compliance programs, and governance activities.